Investment bankers have got rich putting together huge pharmaceuticals companies, such as the $226bn (e226bn) Pfizer-Pharmacia combination announced last week, and they stand to become even richer from taking them apart again.

Senior bankers argue that pharmaceuticals companies have no choice but to continue building scale, despite the destruction of shareholder value from the wave of huge mergers in the industry in the 1990s.